Jacobson Pharma Corporation Limited

HKEX:2633.HK

0.75 (HKD) • At close November 14, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) HKD.

2023 Q42023 Q22022 Q42022 Q22021 Q42021 Q22020 Q42020 Q22019 Q42019 Q22018 Q22017 Q42017 Q22016 Q42016 Q22015 Q42015 Q22014 Q42014 Q32014 Q22014 Q12013 Q42013 Q3
Revenue 752.88714.918968.226817.353845.13750.413750.49695.425699.773871.686816.26805.652743.032680.508575.449565.674518.182236.898236.898231.545231.545231.545231.545
Cost of Revenue 433.484413.839561.483476.924497.45477.571455.664429.168368.312513.169497.566466.894464.128368.232330.837298.349297.752140.721140.721125.335125.335125.335125.335
Gross Profit 319.396301.079406.743340.429347.68272.842294.826266.257331.461358.517318.694338.758278.904312.276244.612267.325220.4396.17796.177106.211106.211106.211106.211
Gross Profit Ratio 0.4240.4210.420.4170.4110.3640.3930.3830.4740.4110.390.420.3750.4590.4250.4730.4250.4060.4060.4590.4590.4590.459
Reseach & Development Expenses 6.4502.12107.5910000001.9064.2346.0910.2513.9641.673000000
General & Administrative Expenses 105.86797.82135.08577.926119.56893.978098.749097.07382.29786.21385.9460.77297.86985.63273.40562.96862.96866.77466.77466.77466.774
Selling & Marketing Expenses 63.91564.775104.64154.39295.49688.591091.73092.20383.23383.11383.96272.74972.60165.48368.324-0.46-0.46-0.455-0.455-0.455-0.455
SG&A 169.782162.595239.726188.344215.064182.569192.142183.437200.005194.936165.53169.326169.902133.521170.47151.115141.72962.50862.50866.3266.3266.3266.32
Other Expenses -23.9890000000000000000000000
Operating Expenses 152.243162.595239.726188.344215.064182.569192.142183.437200.005194.936159.496158.15166.231155.439167.926164.642140.7762.50862.50866.3266.3266.3266.32
Operating Income 167.153138.484167.017152.085132.61690.273102.68482.82131.456163.581154.429170.261109.848179.75274.434116.85479.10333.66933.66939.89139.89139.89139.891
Operating Income Ratio 0.2220.1940.1720.1860.1570.120.1370.1190.1880.1880.1890.2110.1480.2640.1290.2070.1530.1420.1420.1720.1720.1720.172
Total Other Income Expenses Net -31.43-47.445-2.488-9.359-12.822-12.865-7.713-15.7-25.754-6.022-27.218-32.131-11.394-12.091-1.905-0.363-2.160.3650.36514.34614.34614.34614.346
Income Before Tax 135.723118.528164.529178.786131.195104.00694.971131.125105.702157.156127.211152.39398.83144.82376.423104.55678.44134.03434.03454.23754.23754.23754.237
Income Before Tax Ratio 0.180.1660.170.2190.1550.1390.1270.1890.1510.180.1560.1890.1330.2130.1330.1850.1510.1440.1440.2340.2340.2340.234
Income Tax Expense 22.83521.57927.14629.424.68119.04718.90115.36317.82328.20223.83530.56115.76222.85317.13318.31312.0225.5395.5398.0628.0628.0628.062
Net Income 112.928125.823114.852136.19297.62780.03971.2102.51388.413127.21897.531121.94180.329122.27657.05284.4761.1425.47625.47643.08943.08943.08943.089
Net Income Ratio 0.150.1760.1190.1670.1160.1070.0950.1470.1260.1460.1190.1510.1080.180.0990.1490.1180.1080.1080.1860.1860.1860.186
EPS 0.0590.0660.060.0710.0510.0420.0370.0540.0460.0630.0530.0670.0440.0680.0430.0650.0470.0150.0150.0250.0250.0250.025
EPS Diluted 0.0590.0660.060.0710.0510.0420.0370.0540.0460.0630.0530.0670.0440.0680.0430.0650.0470.0150.0150.0250.0250.0250.025
EBITDA 248.122200.229301.469293.751239.032214.453212.164235.777210.63254.307218.249240.552166.254206.387106.942154.173109.15344.92844.92863.64263.64263.64263.642
EBITDA Ratio 0.330.2940.2670.2990.2690.250.2740.2470.3020.2860.2610.2770.2240.3330.1860.2730.2110.190.190.2750.2750.2750.275